Cabozantinib Response in ETV6-NTRK3 G623R Positive Carcinoma HIPO-021

We report a case of marked response to cabozantinib in a secondary entrectinib-resistant tumor harboring the ETV6-NTRK3 fusion with a G623R solvent-front mutation.EGA study EGAS00001004494

我们报道1例携带ETV6-NTRK3融合基因（ETV6-NTRK3 fusion）并带有G623R溶剂前沿突变（solvent-front mutation）的继发性恩曲替尼（entrectinib）耐药肿瘤，该肿瘤对卡博替尼（cabozantinib）展现出显著应答。本研究隶属于欧洲基因组-表型档案（European Genome-phenome Archive, EGA）研究数据集EGAS00001004494。